Skip to content
    AdBio partners logo

    AdBio partners

    Paris, FranceFounded 2016
    adbio.partnersLinkedIn
    Biotech & Life SciencesHealthcare

    AdBio partners (formerly Advent France Biotechnology) is a Paris-based venture capital firm specialized in early-stage investments in the most promising life sciences startups across Europe, focusing on breakthrough medical discoveries in areas such as oncology, immunology, and rare diseases.

    36% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 4 prior). Their most common stage is seed (42% of deals). Average disclosed round size is $54.6M (across 6 rounds with reported amounts).

    Find people at AdBio partners on Goldilocks AI

    Portfolio

    23

    Fund Size

    $102M

    Top Stage

    Seed

    Last 12 Mo

    1

    Team

    AH

    Alain HURIEZ

    Chairman and Managing Partner

    CB

    Clément BERTHOLET

    Managing Partner

    AL

    Aksana LABOKHA

    Venture Partner

    DL

    Didier LECONTE

    Venture Partner

    GD

    Geoffroy DE RIBAINS

    Venture Partner

    JD

    Jacques DUMAS

    Venture Partner

    JC

    Josselin CARADEC

    Venture Partner (Barcelona)

    LD

    Laurence DE SCHOULEPNIKOFF

    Venture Partner

    MA

    Mounia AZZI

    Partner

    PB

    Patrick BURGERMEISTER

    Venture Partner

    AC

    Adrien CLAVAIROLY

    Principal

    SA

    Sofia ARNAL

    Principal

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    33 investments
    CompanyRoundAmountDate
    Tenpoint Therapeutics logoTenpoint TherapeuticsSeries B—Jan 2026
    Arthex Biotech logoArthex BiotechSeries B$87MSep 2025
    AARTHEX BIOTECH S.L.Series B$87MSep 2025
    Augustine Therapeutics logoAugustine TherapeuticsSeries A—Mar 2025
    Augustine Therapeutics logoAugustine TherapeuticsSeries A—Jan 2025
    AAndzonBio1Seed—Oct 2024
    Augustine Therapeutics logoAugustine TherapeuticsSeries A—Jun 2024
    DiogenX logoDiogenXSeries A$33.5MOct 2023
    Astraveus logoAstraveusSeed—Jun 2023
    AAnoat TherapeuticsSeed—Jun 2023
    CCalida TherapeuticsSeed$2MApr 2023
    TTridek-OneUnknown—Jan 2023
    DiogenX logoDiogenXSeries A—Jan 2023
    Astraveus logoAstraveusSeed—Jan 2023
    Orikine Bio logoOrikine BioSeed—Jan 2023
    UUnivercells SASeries D—Oct 2022
    Tridek One logoTridek OneSeries A—Sep 2022
    TTridek-OneUnknown—Sep 2022
    IIntegra TherapeuticsSeed—Mar 2022
    IIntegra TherapeuticsSeed—Dec 2021
    AAlderaan BiotechnologySeries A—Jan 2020
    UUrania TherapeuticsSeed—Nov 2019
    YYukin TherapeuticsUnknown—Jun 2019
    TTridek-OneUnknown—Jun 2019
    TTridek-OneUnknown—Jan 2019
    Page 1 of 2

    Top Co-Investors

    Bpifrance9 shared
    Eli Lilly and Company5 shared
    Columbus Venture Partners4 shared
    Asabys Partners4 shared
    Takeda Ventures, Inc.4 shared
    Gemma Frisius Fund3 shared
    PMV3 shared
    Novo Holdings A/S3 shared
    VIB3 shared
    Bioqube Ventures3 shared
    Pureos Bioventures3 shared
    Boehringer Ingelheim Venture Fund3 shared
    EQT Life Sciences2 shared
    European Innovation Council (EIC)2 shared
    Hadean Ventures2 shared
    Jeito Capital2 shared
    Novo Capital2 shared
    Newton Biocapital2 shared
    Roche Venture Fund2 shared
    Omnes Capital2 shared

    Last updated: 20 October 2026